“A long-acting injectable drug, cabotegravir, is safe and more effective than a daily pill in preventing HIV acquisition, according to results from a study of 3,127 cisgender women in sub-Saharan Africa. Led by UNC researchers beginning in November 2017, the study showed such promising results that a review board recommended ending the blinded phase of the trial early and sharing the results.
‘After years of evaluating HIV prevention strategies for women, I am thrilled that we have found CAB LA so effectively reduces HIV acquisition and provides women more choices in how to protect themselves,’ says Mina Hosseinipour, MD, HPTN 084 co-chair and scientific director of UNC Project-Malawi in Lilongwe, Malawi.”
Many UNC CFAR investigators, including Dr. Hosseinipour, and the CFAR’s international site with UNC Project-Malawi were involved with this study.
This story first appeared November 10, 2020 on the UNC Institute for Global Health and Infectious Diseases website.